logo-loader
FRA:WL6

Heidelberg Pharma AG

Receive alerts
Market:
FRA
Market Cap:
£0.00
Price
£0.00
Change
0%
52 weeks high
0
52 weeks low
0

In brief

Heidelberg Pharma AG, through its subsidiaries, operates as a biopharmaceutical company that focuses on oncology and antibodies, and specializes in antibody drug conjugates (ADCs) in Germany, Europe, the United States, China, and Australia. It is developing HDP-101, an antibody targeted amanitin conjugate (ATAC) candidate for the treatment of multiple myeloma; PSMA, an ATAC candidate to treat prostate cancer; CD19, an ATAC candidate for the treatment of haematological tumors; HuMAB 5B1, an ATAC candidate to treat metastatic pancreatic cancer; and NN, an ATAC candidate for treating leukemia.